

## HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC)

### TOUJEO® (INSULIN GLARGINE 300 UNITS/ML) IMPLEMENTATION PLAN FOR HVCCG & ENHCCG

Action required:	Actions required/by:
<b>Toujeo® to be initiated by specialists only</b> (as it is not bioequivalent/interchangeable with Lantus® & blood glucose monitoring and dosage adjustment required) i.e. amber initiation.	<b>Diabetes specialists</b> to initiate, titrate and stabilise patients on Toujeo® (minimum 3 months or until stable) prior to continuation by primary care.
<b>Only Toujeo® Solostar (1.5ml pens) approved for use.</b> i.e. Toujeo® Doublestar (3ml pens) <b>NOT</b> approved for use within Hertfordshire.	<b>All</b> – to annotate formularies/prescribe accordingly.
<b>Education for patients</b> regarding use of a new insulin product/use of a high-strength insulin.	<b>Initiating diabetes specialists.</b>
<b>Use of ‘insulin passports’.</b>	<b>Initiating specialists</b> to issue insulin passport to all patients initiated on Toujeo®.
	<b>All healthcare professionals</b> to refer to patient’s insulin passport at point of prescribing, dispensing or administration.
<b>Toujeo® should be prescribed by brand name;</b> prescriptions should also include the strength and device (i.e. Toujeo® should <b>not</b> be prescribed as insulin glargine).	<b>All prescribers</b> (primary and secondary care). <b>CCGs</b> to add GP prescribing system message (via ScriptSwitch) to generic insulin glargine 300units/ml to advise brand prescribing.
<b>Education for hospital staff</b> regarding availability of a new insulin product/use of a high-strength insulin.	<b>Provider organisations</b> via newsletters/medication safety training sessions or equivalents, with initial and on-going reinforcement by ward pharmacy staff to consolidate learning.  The availability/use of high-strength insulin also to be included in routine staff induction training (as part of medication safety programmes) for all staff involved in prescribing/administering insulins. To include use of pre-recorded videos (if/when available – see below) that can be shared via platforms e.g. WhatsApp, Telegram).  <b>Diabetes Nurse Specialists</b> to include in routine training sessions for nurses/healthcare professionals.
<b>Review by provider organisations of existing policies/procedures.</b> To include need to:	<b>Provider organisations.</b>

<ul style="list-style-type: none"> <li>• review storage to mitigate risk of picking errors;</li> <li>• review paper/electronic prescribing systems (to reduce the risk of prescribing errors), e.g. for electronic systems: consider use of ‘pop-up’ warnings / removal of option for generic insulin glargine;</li> <li>• amend dispensing system (where possible) to add a warning that Toujeo® is a high-strength insulin;</li> <li>• ensure systems are in place to ensure pharmacy personnel clarify the insulin product and presentation during medicines reconciliation;</li> <li>• use of retractable pen needles where patients unable to self-administer.</li> </ul>	
<p><b>Education for community pharmacy staff.</b>          To include:</p> <ul style="list-style-type: none"> <li>• availability of a new insulin product/use of a high-strength insulin;</li> <li>• need to review storage to mitigate risk of picking errors;</li> <li>• need to amend dispensing system (where possible) to add a warning that Toujeo® is a high-strength insulin.</li> </ul>	<p>Information to be circulated by <b>CCGs</b> in newsletters to community pharmacies.</p> <p><b>Local Pharmaceutical Committee (LPC)</b> also to circulate information via newsletter and at LPC community pharmacy meetings.</p>
<p><b>Education for GPs and practice staff.</b>          regarding:</p> <ul style="list-style-type: none"> <li>• availability of a new insulin product/use of a high-strength insulin;</li> <li>• need to consider reviewing paper/electronic prescribing systems (to reduce the risk of prescribing errors), e.g. for electronic systems: consider use of ‘pop-up’ warnings / removal of option for generic insulin glargine.</li> </ul>	<p>Information to be circulated by <b>CCG</b> in newsletters to GPs, practice nurses and GP clinical pharmacists. Also to be raised by CCGs at GP prescribing lead meetings.</p> <p><b>GP practices</b> – information to be included in medication safety training sessions or equivalent, with initial and on-going reinforcement by <b>GP/PCN pharmacists</b> and <b>Diabetes Nurse Specialists</b>.</p> <p><b>GP practices</b> – the availability/use of high-strength insulin also to be included in routine staff induction training (as part of medication safety programmes) for all staff involved in prescribing/administering insulins. To include use of pre-recorded videos (if/when available – see below) that can be shared via platforms e.g. WhatsApp, Telegram).</p>
<p><b>Education for community healthcare professionals</b> regarding availability of a new insulin product/use of a high-strength insulin (to include need to use retractable pen needles where patients unable to self-administer).</p>	<p>Information to be circulated to community nursing team via <b>CLCH</b> and <b>HCT</b> (i.e. for staff in ENHCCG &amp; HVCCG).</p> <p>The availability/use of high-strength insulin also to be included in routine staff induction</p>

	training (as part of medication safety programmes) for all staff involved in prescribing/administering insulins. To include use of pre-recorded videos (if/when available – see below) that can be shared via platforms e.g. WhatsApp, Telegram).
<b>Education for care home staff</b> regarding availability of a new insulin product/use of a high-strength insulin (to include need to review storage to mitigate risk of picking errors & need to use retractable pen needles where patients unable to self-administer).	Information to be circulated via Herts Care Providers Association, (instigated by <b>CCG</b> ). On-going reinforcement by CCG care home pharmacists and GP/PCN pharmacists.
<b>Development of educational video</b> on insulin glargines to raise awareness of availability of high-strength insulins/biosimilars.	<b>CCG</b> to liaise with EDEN training team (Herts Valleys integrated Diabetes Service), to request development of training video suitable for use by primary and secondary care healthcare professionals <b>across Hertfordshire</b> . For use by EDEN training team, ENH speciality team, & to be made available on HVCCG & ENHCCG websites.

<b>Version</b>	1.0
<b>Developed by</b>	Dr Thomas Galliford (Diabetes Clinical Lead for HIDS) Dr Nicola Cowap (HVCCG GP Clinical Lead – Diabetes) Cathy Geeson (Interface Pharmacist, HVCCG) Phyllis Renehan (Diabetes Nurse Specialist, WHHT)
<b>Date ratified</b>	Version 1.0 July 2020 Herts Medicines Management Committee
<b>Review date</b>	N/A